Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
09/2005
09/20/2005CA2170606C Type i angiotensin ii receptor specific monoclonal antibodies and hybridomas
09/15/2005WO2005085456A1 New expression tools for multiprotein applications
09/15/2005WO2005085446A1 Method of selecting bird resistant to rna virus
09/15/2005WO2005085445A1 Recombinant varicella-zoster virus
09/15/2005WO2005085291A1 A kind of fusion protein, gene encoding it, expression method and use thereof
09/15/2005WO2005085288A2 Natural igm antibodies and inhibitors thereof
09/15/2005WO2005085278A1 Fusion proteins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same
09/15/2005WO2005084708A1 Medicinal composition containing cxcr3 inhibitor
09/15/2005WO2005084707A1 Method of utilizing organic cation transporter oct3-related molecule for treating mental diseases such as depression, anxiety neurosis, drug addiction and the like
09/15/2005WO2005084706A1 Mutant strains of brucella melitensis and immunogenic compositions
09/15/2005WO2005084705A1 Botulinum toxin treatments of neurological and neuropsychiatric disorders
09/15/2005WO2005084704A1 Digestive bypass composition for arthropod and uses thereof
09/15/2005WO2005084646A1 Powdered compositions of sensitive active materials in an at least partially amorphous state
09/15/2005WO2005084444A1 Compositions and methods for the treatment and clinical remission of psoriasis
09/15/2005WO2005084427A1 Preparation of recombinant rotavirus proteins in milk of transgenic non human mammals
09/15/2005WO2005084410A2 Compositions and methods for topical application and transdermal delivery of botulinum toxins
09/15/2005WO2005084387A2 Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
09/15/2005WO2005084329A2 Method for inhibiting tumor formation and growth
09/15/2005WO2005084314A2 Audioligical treatment system and methods of using the same
09/15/2005WO2005084306A2 Immunogenic compositions for chlamydia pneunomiae
09/15/2005WO2005084208A2 A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
09/15/2005WO2005084198A2 Peptides of il1 beta and tnf alpha and method of treatment using same
09/15/2005WO2005058351A3 Treatment of rheumatoid arthritis with soluble fas-ligand cross-linkers
09/15/2005WO2005051421A3 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo
09/15/2005WO2005049084A3 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
09/15/2005WO2005047458A3 Modified recombinant vaccina viruses and other microorganisms, uses thereof
09/15/2005WO2005046711A3 Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing
09/15/2005WO2005044982A3 Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
09/15/2005WO2005044306A3 Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
09/15/2005WO2005044294A3 Method of therapy for cancers expressing the cd40 antigen
09/15/2005WO2005034841A3 Anthrax vaccine
09/15/2005WO2005023837A3 Ebola peptides and immunogenic compositions containing same
09/15/2005WO2005019249A3 Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
09/15/2005WO2005018536A3 Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
09/15/2005WO2005016232A3 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
09/15/2005WO2005010151A3 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
09/15/2005WO2004084823A3 Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
09/15/2005WO2004056307A3 Disease treatment via antimicrobial peptide inhibitors
09/15/2005WO2003085087A8 Modified cea nucleic acid and expression vectors
09/15/2005WO2002048388A3 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
09/15/2005US20050204415 Methods of blocking tissue destruction by autoreactive T cells
09/15/2005US20050204414 Methods of blocking tissue destruction by autoreactive T cells
09/15/2005US20050204413 Methods of blocking tissue destruction by autoreactive T cells
09/15/2005US20050204412 Artery- and vein-specific proteins and uses therefor
09/15/2005US20050203280 Nucleotide sequences coding gramnegative microorganismal genomic sequences for use as tool in diagnosing middle ear infection
09/15/2005US20050203158 Substituted benzimidazole compounds
09/15/2005US20050203057 Treatment of cancers
09/15/2005US20050203036 Compositions and methods for treating hematologic malignancies and multiple drug resistance
09/15/2005US20050203024 Peptides and methods for inducing cellular resistance to infection
09/15/2005US20050202553 Animal cells and processes for the replication of influenza viruses
09/15/2005US20050202540 Methods of producing hyaluronic acid using a recombinant hyaluronan synthase gene
09/15/2005US20050202529 Humanised antibodies
09/15/2005US20050202481 Novel polypeptide ESDN, polynuleotides encoding the polypeptide, and utility of the polypeptide
09/15/2005US20050202454 "STRAP" and "STEAP"(six transmembrane (epithelial) antigen of the prostate)
09/15/2005US20050202442 Novel therapeutic targets in cancer
09/15/2005US20050202418 HCV peptide compositions
09/15/2005US20050202415 Coronavirus amino acid sequences for use in prevention and treatment of infection and cell proliferative disorders
09/15/2005US20050202098 Administering leukocytes to suppress immune response; autoimmune diseases; graft versus host disease
09/15/2005US20050202048 Chlamydia antigens and vaccine uses of the protein
09/15/2005US20050202047 Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
09/15/2005US20050202046 Canine vaccine for protection against ehrlichiosis
09/15/2005US20050202045 Recombinant avian herpesvirus useful in vaccine production
09/15/2005US20050202044 A fusion protein containing an antigen of an influenza virus and a bacterial stress protein; vaccines induce a cytolytic T-cell (CTL) response in a mammal
09/15/2005US20050202043 Multimerised HIV fusion inhibitors
09/15/2005US20050202042 Toxin B repeating units (rBRU) of Clostridium difficile and an antigen of a pathogenic microorganism other than C. difficile; eliciting T-cell dependent and antibody responses
09/15/2005US20050202041 Peanut skin extract; strong immunostimulatory effect on the protective effects of live coccidiosis vaccines in ovo
09/15/2005US20050202039 Renibacterium salmoninarum vaccine
09/15/2005US20050202037 Group a streptococcal vaccines
09/15/2005US20050202036 Alternate reading frame polypeptides drived from hepatitis C and methods of their use
09/15/2005US20050202035 Stress protein complex; a grp170 polypeptide and an immunogenic polypeptide; antitumor
09/15/2005US20050202034 polypeptide relating to the autoimmune disease pemphigus vulgaris
09/15/2005US20050202033 Heat shock protein-based vaccines and immunotherapies
09/15/2005US20050202032 Use of neglected target tissue antigens in modulation of immune responses
09/15/2005US20050202031 Immunoglobulin specific to insect hydrolase for use in treatment and prevention of animal hyperimmune response to flea exposure; biological control agent
09/15/2005US20050202030 Method of evaluating the therapeutic potential of a vaccine for mucosal administration
09/15/2005US20050202029 Administering to reduce an immune response by modulating the trafficking of leukocytes
09/15/2005US20050202027 Multivalent compounds for crosslinking receptors and uses thereof
09/15/2005US20050202025 Antibodies to the FbsA protein of streptococcus agalactiae and their use in treating or preventing infections
09/15/2005US20050202024 Protein sequences containing antigenized antibodies for foot-and-mouth disease
09/15/2005US20050202022 Polynucleotides encoding humanized antibodies against human 4-1BB
09/15/2005US20050202021 Anti-cancer antibodies with reduced complement fixation
09/15/2005US20050202020 Diagnosing and treating cancer
09/15/2005US20050202019 Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
09/15/2005US20050202018 Binding agent, conjugated to a keyhole limpet hemocyanin, that specifically binds to circulating prostate specific antigen and induces a therapeutic immune response
09/15/2005US20050202017 Assay; contacting a test compound with a HB-954 polypeptide; determining whether the test compound binds to the G protein-coupled receptor
09/15/2005US20050202016 Polypeptide; an amino acid sequence of the family of tumour-suppressing genes related to the gene for the p53 protein; isolated nucleic acid sequences coding for the proteins
09/15/2005US20050202014 Methods of blocking tissue destruction by autoreactive T cells
09/15/2005US20050202013 Novel Th2-specific molecules and uses thereof
09/15/2005US20050202011 Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
09/15/2005US20050202010 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
09/15/2005US20050202009 Novel MHC II associated peptides
09/15/2005US20050202008 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
09/15/2005US20050202007 Determining a P-selectin activity in a biological sample of the subject,increased P-selectin activity in the sample indicates a procoagulant state in the subject
09/15/2005US20050202003 Methods for sterilizing preparations of monoclonal immunoglobulins
09/15/2005US20050201993 Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
09/15/2005US20050201992 Culture with human dendritic cells wherein the hybrid cells were generated by fusing tumor cells dissociated from a tumor by mechanical dissociation with a highly enriched population of human B-cells; avoiding the problems of immune suppression, autoimmune reactions, and self-recognition; kits; antitumor
09/15/2005US20050201986 Cell targeting compositions and methods of using the same
09/15/2005US20050201979 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders
09/15/2005US20050201973 Therapeutic supramolecules
09/15/2005US20050201952 Treatment and prevention of viral hepatitis infections
1 ... 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 ... 1823